Irinotecan is indicated for single agent or combination therapy of various type of tumors: Metastatic carcinoma of the colon or rectum that has recurred or progressed following 5‑fluorouracil (5‑FU)‑based therapy; Previously untreated metastatic carcinoma of the colon or rectum; Irinotecan combined with cetuximab is indicated for the treatment of patients with epidermal growth factor receptor (EGFB)‑expressing metastatic colorectal cancer after failure of irinotecan‑including cytotoxic therapy; Irinotecan combined with 5 FU, folinic acid (FA) and bevacizumab is indicated for first‑line treatment of patients with metastatic carcinoma of the colon or rectum; Cervical cancer; Ovarian cancer; Non‑small‑cell lung cancer; Small‑cell lung cancer; Inoperable or recurrence gastric cancer; Esophageal cancer; Malignant Glioma.
Sign Out
